Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
SMIC Allegedly Supplies Chipmaking Tools to Iran's Military, U.S. Officials Warn 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Apple Turns 50: From Garage Startup to AI Crossroads 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
PARSIPPANY, N.J., Jan. 03, 2017 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Dave Stack, Chief Executive Officer and Chairman of Pacira Pharmaceuticals, is scheduled to present at the 35th Annual J.P. Morgan Healthcare Conference at 3:30 p.m. PT (6:30 p.m. ET) on Monday, January 9, 2017, in San Francisco. Mr. Stack is expected to present an overview of the company.
A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), a non-opioid local analgesic for postsurgical pain control, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Company Contact: Pacira Pharmaceuticals, Inc. Susan Mesco, (973) 451-4030 [email protected]
